Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics (LPTX - Research Report) today and set a price target of $6.00. The company's shares closed today at $1.35.According to TipRanks, Goldstein is a 3-star analyst with an average return of 2.7% and a 35.69% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Leap Therapeutics with a $4.83 average price target, implying a 257.78% upside from current levels. In a report released on September 6, Robert W.
https://www.tipranks.com/news/blurbs/leap-therapeutics-lptx-receives-a-buy-from-mizuho-securities-3?utm_source=advfn.com&utm_medium=referral
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Leap Therapeutics Charts.
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Leap Therapeutics Charts.